{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:05Z","timestamp":1791593825056,"version":"4.3.4"},"reference-count":102,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.1080\/14712598.2025.2561935","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:16:44Z","timestamp":1759159004000},"page":"1047-1058","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["An evaluation of nipocalimab for the treatment of generalized myasthenia gravis"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico C. Besta","place":["Milan, Italy"]},{"name":"Fondazione IRCCS Istituto Neurologico C. Besta","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Raritan, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000539577"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823912-4.00026-8"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00357-4"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.17925\/ENR.2018.13.1.18"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03553-y"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000377"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502480"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00916-w"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329284"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1370411"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01090-3"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00810"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00708-2"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.108910"},{"key":"e_1_3_7_25_1","unstructured":"Efgartigimod alfa US PI. [cited 2025 May]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761195s004 761304s003lbl.pdf"},{"key":"e_1_3_7_26_1","unstructured":"Efgartigimod alfa SmPC. [cited 2025 May]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_3_7_28_1","unstructured":"Rozanolixizumab US PI. [cited 2025 May]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761286s001lbl.pdf"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464"},{"key":"e_1_3_7_30_1","unstructured":"Rozanolixizumab SmPC. [cited 2025 May]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rystiggo-epar-product-information_en.pdf"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191"},{"key":"e_1_3_7_32_1","unstructured":"Nipocalimab US PI. [cited 2025 May]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0044"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b907b"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00408-x"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00617-6"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00285-w"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28063"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52122"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03869-9"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208718"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001220"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00097"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211310"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28038"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123180"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0391-5"},{"key":"e_1_3_7_54_1","unstructured":"Arumugham VB Rayi A. Intravenous immunoglobulin (IVIG). Treasure Island (FL): StatPearls Publishing; 2023. [cited 2025 Jul]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554446\/"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.08.011"},{"issue":"2","key":"e_1_3_7_56_1","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh J","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013 Jun;86(2):255\u2013260.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09667-5"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.725700"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086225"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03014-5"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2082946"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241301361"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70158"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08128-4"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01380-0"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00748-4"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12247-x"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01062-7"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1280226"},{"key":"e_1_3_7_74_1","unstructured":"Jacob S Hashim M Hutton B et al. Comparative efficacy of nipocalimab and other FcRn blocker therapies in generalized myasthenia gravis. Presented at the 11th European Academy of Neurology (EAN) Congress. Helsinki Finland. 2025 Jun 21\u201324 [cited 2025 Aug]. Available from: https:\/\/www.jnjmedicalconnect.com\/media\/attestation\/congresses\/neuroscience\/2025\/ean\/comparative-efficacy-of-nipocalimab-and-other-fcrn-blocker-therapies-in-generalized-myasthenia-gravi.pdf"},{"key":"e_1_3_7_75_1","volume-title":"American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting","author":"Muppidi S","year":"2025","unstructured":"Muppidi S, Corse A, Wiendl H, et al. Efficacy and safety of nipocalimab vs efgartigimod in a randomized, open-label, phase 3b, interventional trial including within class switching from efgartigimod to nipocalimab (EPIC): study design. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; 2025 Oct 29\u2013Nov 1; San Francisco, CA, USA; 2025. https:\/\/online.flippingbook.com\/view\/442003187\/115\/"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1826"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.407"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206348"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2023.11.528"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.02.058"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314466"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203877"},{"key":"e_1_3_7_89_1","volume-title":"Presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting","author":"Farmakidis C","year":"2024","unstructured":"Farmakidis C. Symptom severity assessment using MG-ADL items and domains in a 24-week, phase 3 study (Vivacity) of nipocalimab in generalized myasthenia gravis. In: Presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; Savanah (GA); 2024 Oct 15\u201318."},{"key":"e_1_3_7_90_1","first-page":"707","article-title":"Nipocalimab, a new neonatal fragment crystallizable blocker, leads to rapid, substantial and sustained generalized myasthenia gravis disease control [abstract number: mG97]. Presented at MGFA 2024","volume":"70","author":"Nowak R","year":"2024","unstructured":"Nowak R, Ait-Tihyaty M, Turkoz I, et al. Nipocalimab, a new neonatal fragment crystallizable blocker, leads to rapid, substantial and sustained generalized myasthenia gravis disease control [abstract number: mG97]. Presented at MGFA 2024. Muscle & Nerve. 2024 [cited 2025 Aug];70:707. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.28233","journal-title":"Muscle & Nerve"},{"key":"e_1_3_7_91_1","volume-title":"Presented at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference","author":"Beydoun SR","year":"2025","unstructured":"Beydoun SR. Composite response to nipocalimab, a novel FcRn blocker, based on MG-ADL and quantitative MG scores in patients with generalized myasthenia gravis. In: Presented at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference; The Netherlands. The Hague; 2025 May 13\u201315, 2025."},{"key":"e_1_3_7_92_1","volume-title":"11th Congress of the European Academy of Neurology 2025","author":"Claeys KG","unstructured":"Claeys KG, et al. Efficacy of nipocalimab in adult patients with moderate to severe ocular manifestations of gMG in phase 3 VIVACITY-MG3. In: 11th Congress of the European Academy of Neurology 2025; 2025 June 21\u201324; Helsinki, Finland."},{"key":"e_1_3_7_93_1","volume-title":"Presented at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference","author":"Katzberg H","year":"2025","unstructured":"Katzberg H. Safety profile of nipocalimab, a new neonatal fragment crystallizable receptor blocker in the phase 3 vivacity study. In: Presented at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference; The Netherlands. The Hague; 2025 May 13\u201315."},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211115"},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211115"},{"key":"e_1_3_7_96_1","unstructured":"NCT05265273. [cited 2025 May]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05265273"},{"key":"e_1_3_7_97_1","volume-title":"Presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting","author":"Strober J","year":"2024","unstructured":"Strober J, et al. Abstract 276. Safety and effectiveness of nipocalimab in adolescent participants in the open label phase 2\/3 Vibrance-MG clinical study. In: Presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; Savanah (GA); 2024 [2024 Oct 15\u201318]."},{"key":"e_1_3_7_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2491269"},{"key":"e_1_3_7_99_1","unstructured":"European Medicines Agency. Imaavy. European Medicines Agency; 2025 Sep 22. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imaavy"},{"key":"e_1_3_7_100_1","unstructured":"Johnson & Johnson Japan. New FcRn inhibitor \u201cImaavy\u00ae (generic name: nipocalimab)\u201d receives manufacturing and marketing approval for generalized myasthenia gravis providing sustained symptom control for a wide range of patients with generalized myasthenia gravis [Article in Japanese]. 2025 Sep 19. https:\/\/innovativemedicine.jnj.com\/japan\/press-release\/20250919"},{"key":"e_1_3_7_101_1","unstructured":"National Health Surveillance Agency - Anvisa. MAAVY (nipocalimab): new registration [article in Portugese]. 2025. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/imaavy-nipocalimabe-novo-registro"},{"key":"e_1_3_7_102_1","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1416202551"},{"key":"e_1_3_7_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-024-02552-7"},{"key":"e_1_3_7_104_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"}],"updated-by":[{"DOI":"10.1080\/14712598.2025.2610041","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000}}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2561935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:35:15Z","timestamp":1768376115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2561935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":102,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"alternative-id":["10.1080\/14712598.2025.2561935"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2561935","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}